



*General Principles for the Diagnosis and Management of Asthma*

The following guideline recommends general principles and key clinical activities for the diagnosis and management of asthma.

Eligible Population	Key Components	Recommendation and Level of Evidence
<p>Children and adults with the following:</p> <p>Wheezing</p> <p>History of cough (worse particularly at night), recurrent wheeze, recurrent difficulty in breathing, recurrent chest tightness</p> <p>Symptoms occur or worsen in the presence of exercise, viral infection, inhalant allergens, irritants, changes in weather, strong emotional expression (laughing or crying hard), stress, menstrual cycles</p> <p>Symptoms occur or worsen at night, awakening the patient</p>	<p>Diagnosis and management goals</p>	<p>Detailed medical history and physical exam to determine that symptoms of recurrent episodes of airflow obstruction are present</p> <p>Use spirometry (FEV<sub>1</sub>, FEV<sub>6</sub>, FVC, FEV<sub>1</sub>/FVC) in all patients ≥ 5 years of age to determine that airway obstruction is at least partially reversible [C]</p> <p>Consider alternative causes of airway obstruction</p> <p><b>Goals of therapy are to achieve control by:</b></p> <p>Reducing impairment: chronic symptoms, need for rescue therapy and maintain near-normal lung function and activity level [A]</p> <p>Reducing risk: exacerbations, need for emergency care or hospitalization, loss of lung function or reduced lung growth in children, or adverse effects of therapy [A]</p>
	<p>Assessment and monitoring</p>	<p>Assess asthma severity to initiate therapy using <a href="#">severity classification chart</a> for impairment [B] and risk [C]</p> <p>Assess asthma control to monitor and adjust therapy [B]. (Use <a href="#">asthma control chart</a>, for impairment and risk. Step up if necessary; step down if possible.)</p> <p>Obtain spirometry (FEV<sub>1</sub>, FEV<sub>6</sub>, FVC, FEV<sub>1</sub>/FVC) to confirm control after symptoms have stabilized; and, at least every 1-2 years [B], more frequently for not well-controlled asthma.</p> <p><b>Schedule follow-up care: within 1 week, or sooner, if acute exacerbation; at 2- to 6-week intervals while gaining control [D]; monitor control at 1- to 6-month intervals, at 3-month interval if a step-down in therapy is anticipated [D]</b></p> <p>Assess asthma control, medication technique, written asthma action plan, patient adherence and concerns at every visit.</p>
	<p>Education</p>	<p>Develop written <a href="#">asthma action plan</a> in partnership with patient/family/caregiver [B]. Update annually, more frequently if needed.</p> <p>Provide self-management education [A]. Teach and reinforce: self-monitoring to assess control and signs of worsening asthma (either symptoms or peak flow monitoring) [B]; using written asthma action plan; taking medication correctly (inhaler technique and use of devices); avoiding environmental and occupational factors that worsen asthma.</p> <p>Tailor education to literacy level of patient; appreciate potential role of patient's cultural beliefs and practices in asthma management [C]</p>
	<p>Control environmental factors and comorbid conditions</p>	<p>Recommend measures to control exposures to allergens, tobacco smoke, pollutants, or other irritants (dust, mold) that make asthma worse [A]</p> <p>Consider allergen immunotherapy for patients with persistent asthma and when there is clear evidence of a relationship between symptoms and exposure to an allergen to which the patient is sensitive [B]</p> <p>Treat comorbid conditions (e.g., allergic bronchopulmonary aspergillosis [A], gastroesophageal reflux [B], obesity [B], obstructive sleep apnea [D], rhinitis and sinusitis [B], chronic stress or depression [D])</p> <p>Inactivated influenza vaccine for all patients over 6 months of age [A] unless contraindicated. Do not use intranasal influenza vaccine.</p> <p>Give 23-valent pneumococcal polysaccharide vaccine (PPSV23) age 19 and older (age 2-18 if using high-dose oral steroids)</p>
	<p>Medications (See link to national age-specific guidelines<sup>1</sup> for treatment recommendations)</p>	<p>Initial treatment should be based on the severity of asthma, both impairment and risk.</p> <p><b>Inhaled corticosteroids (ICS) are the most effective long-term control therapy [A]. Optimize ICS use before advancing to other therapies.</b></p> <p>Re-evaluate in 2 - 6 weeks for control. Modify treatment based on level of control.</p> <p>Consider step down if well-controlled for 3 months.</p> <p>Warning for use of Long-acting beta-agonists (LABA). See Black Box Warning:</p> <ul style="list-style-type: none"> <li>◆ <b>Do not use LABA as monotherapy.</b> Use only with an asthma controller such as inhaled corticosteroids.</li> <li>◆ Use for the shortest duration possible.</li> <li>◆ Only use if not controlled on medium-dose ICS.</li> <li>◆ Pediatric and adolescent patients who require the addition of a LABA to an inhaled corticosteroid should use a combination product containing both.</li> </ul>
<p>Referral</p>	<p>Consider referral to an asthma specialist for consultation or co-management if there are difficulties achieving or maintaining control (See national age-specific guidelines<sup>1</sup>), immunotherapy or omalizumab is considered, additional testing is indicated, or if the patient required 2 bursts of oral corticosteroids in the past year or a hospitalization [D].</p>	

<sup>1</sup>[NHLBI 2007 EPR3](#): Guidelines for the Diagnosis and Management of Asthma. Stepwise Approach for Managing Asthma Long Tern, Figures 13 and 16.

**Levels of Evidence for the most significant recommendations:** A = randomized controlled trials; B = controlled trials, no randomization; C = observational studies; D = opinion of expert panel

This guideline lists core management steps. It is based on 2007 National Asthma Education and Prevention Program Expert Panel Report 3, Guidelines for the Diagnosis and Management of Asthma. National Heart, Lung and Blood Institute; NHLBI Asthma Care Quick Reference Diagnosing and Managing Asthma NIH Publication No. 12-5075, Revised September 2012; Advisory Committee on Immunization Practices, Pneumococcal ACIP Vaccine Recommendations (cdc.gov).